PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $95.00 at Wells Fargo & Company

PTC Therapeutics (NASDAQ:PTCT) had its price objective raised by Wells Fargo & Company from $86.00 to $95.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the company. Bank of America reduced their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Morgan Stanley upped their target price on PTC Therapeutics from $90.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Jefferies Financial Group lowered PTC Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $91.00 to $76.00 in a research report on Monday, March 30th. Raymond James Financial assumed coverage on PTC Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $108.00 target price on the stock. Finally, Barclays reaffirmed an “overweight” rating and set a $120.00 target price on shares of PTC Therapeutics in a research report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.36.

PTC Therapeutics Trading Up 14.3%

Shares of PTCT stock opened at $73.69 on Friday. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $87.50. The stock has a market capitalization of $6.11 billion, a price-to-earnings ratio of -31.63 and a beta of 0.53. The stock has a fifty day simple moving average of $67.69 and a two-hundred day simple moving average of $72.07.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.42. The firm had revenue of $272.55 million during the quarter, compared to analyst estimates of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The business’s revenue for the quarter was up 43.5% compared to the same quarter last year. During the same period in the previous year, the company posted $10.04 EPS. Research analysts predict that PTC Therapeutics will post -1.1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Mark Elliott Boulding sold 3,081 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $213,698.16. Following the sale, the vice president directly owned 108,231 shares of the company’s stock, valued at $7,506,902.16. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew B. Klein sold 7,371 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the sale, the chief executive officer directly owned 387,082 shares in the company, valued at approximately $26,848,007.52. This trade represents a 1.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 126,492 shares of company stock valued at $8,634,621. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds have recently bought and sold shares of the business. UMB Bank n.a. purchased a new position in PTC Therapeutics during the fourth quarter worth approximately $26,000. Smartleaf Asset Management LLC boosted its position in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. boosted its position in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank boosted its position in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in PTC Therapeutics during the fourth quarter worth approximately $41,000.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.